Lung cancer is the most common cancer worldwide and on top of that has a very poor prognosis, which is reflected by a 5-year survival rate of 5-15%. Radiotherapy is an integral part of most treatment regimens for this type of tumor, often combined with radiosensitizing cytotoxic drugs. In this study, we identified many genes that could potentially be exploited for targeted radiosensitization using a genome-wide siRNA screen in non-small cell lung cancer (NSCLC) cells. The screen identified 433 siRNAs that potentially sensitize lung cancer cells to radiation. Validation experiments showed that knockdown of expression of Forkhead box M1 (FOXM1) or microtubule associated serine/threonine kinase-like (MASTL) indeed causes radiosensitization in a panel of NSCLC cells. Strikingly, this effect was not observed in primary human fibroblasts, suggesting that the observed radiosensitization is specific for cancer cells. Phosphoproteomics analyses showed that a number of cell cycle related proteins are significantly less phosphorylated after MASTL knockdown, whereas the levels of phosphorylation of DNA damage response proteins is not changed after application of irradiation. Subsequent analyses showed that MASTL knockdown cells respond differently to radiation, with a significantly shortened G2/M-phase arrest and defects in cytokinesis, which are followed by a cell cycle arrest. In summary, we have identified many potential therapeutic targets that could be used for radiosensitization of NSCLC cells, with MASTL being a very promising and druggable target to combine with radiotherapy.
Introduction
Lung cancer is the most frequently diagnosed cancer, representing 12% of all cancers worldwide (1) . It is a heterogeneous disease and is divided into multiple classes. The major division is made between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which make up 20% and 80% of the lung cancer cases, respectively (2) . It has been shown that the different subtypes of lung cancer exhibit large variations in sensitivity to cytotoxic compounds and radiation, where SCLC was shown to be the most sensitive (3) .
Clinical treatment regimens for lung cancer consist of surgery, radiotherapy or chemotherapy, but often a combination of these modalities is applied. Radiotherapy is an integral part in almost all treatment schedules for lung cancer (4) . Despite an initial remission after the start of treatment, a relapse is frequently observed after which the tumor can no longer be treated effectively (5) . The lack of treatment efficacy has become a major obstacle in the curative treatment of lung cancer, which is reflected in the current five year survival rate for lung cancer patients of only 5-15% (6) .
It has become clear that the tumor subtype and the presence of specific genetic aberrations in the tumor cell determine the intrinsic capacity to respond to therapy. Several studies have shown that specific mutations, for example in components of the EGFR pathway, are associated with a more radioresistant phenotype in NSCLC (7, 8) . The identification of genes involved in radiation response in lung cancer could therefore provide leads for novel druggable targets that could be exploited to enhance radiotherapy-containing treatment modalities. Here we report the results of a genome-wide loss of function screen and the identification of multiple novel targets that may cause radiosensitization in NSCLC cells when inhibited. 
Materials and methods

Cell culture
All cell lines used were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum (FCS), 2 mM L-glutamine and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO 2 at 37°C. Non-small cell lung cancer cell lines SW1573, A549, H322 and H1299 were obtained from the Department of Medical Oncology (VU University medical centre, Amsterdam), which were authenticated by TP53 sequencing. Hek293T cells were a kind gift from Peter Heutink (VU University medical centre, Amsterdam). Human fibroblasts were isolated from uvulopalatopharyngoplasty specimen. Use of residual tissue from surgical specimen was according to the guidelines of the Dutch federation of Biomedical Scientific Societies and Dutch legislation.
siRNA screens
The SW1573 NSCLC cell line was subjected to a high-throughput forward transfection in 96-well plates as described before (9) . Cells were seeded at a density of 200 cells per 96-well and were transfected 24 hours later. In total 25 nmol of each siRNA SMARTpool derived from the siARRAY Human Genome library (Catalog items G-003500 (Sept05), G-003600 (Sept05), G-004600 (Sept05) and G-005000 (Oct05); and 0.01% v/v DharmaFECT1 (Thermo Fisher Scientific) were delivered to the cells. The nontargeting siCONTROL#2, siPLK1 and siPRKDC (Thermo Fisher Scientific) were used as negative control, transfection control and radiosensitization control, respectively. Plates were left for 48 hours and subsequently irradiated with a dose of 2 Gy of γ-radiation using a 60 Co source (Gammacell 220; MDS Nordion). In total, 96 hours after irradiation the cells were fixed and stained for 1 hour with a 3.7% formaldehyde solution in H 2 O containing 0.5 µg/ml Hoechst 33342. The number of stained nuclei was determined using the Acumen eX3 microplate cytometer (TTP LabTech). 
Deconvolution of siRNA pools
To confirm the hits from the primary screen, SW1573 cells were transfected with the individual siRNAs from the siRNA pool used in the initial screen. Cells were transfected with 25 nmol siRNA and 0.015% v/v DharmaFECT1. Cells were irradiated with a dose of 2 Gy and cell viability was measured 96 hours post-irradiation using staining with Hoechst 33342 and Acumen analysis as described above.
Lentiviral transduction
Stable shRNA expressing cell lines were generated by transduction of target cells (SW1573, A549, H1299 and H322) with lentiviral particles containing specific shRNAs targeting MASTL and FOXM1. Lentiviral particles were produced by Hek293T cells after transfection with the shRNA encoding pLKO.1 plasmids and the corresponding lentiviral helper constructs (Sigma-Aldrich).
Quantitative RT-PCR
Total RNA was extracted from cell lines using the RNeasy micro kit (Qiagen) or with TRIzol (Invitrogen) for small or large number of cells, respectively. Complementary DNA was synthesized using a high capacity cDNA reverse transcription kit (Applied Biosystems) (10) .
Amplification of the cDNA was performed on the ABI/Prism 7500 Sequence Detector System with universal PCR master mix (Applied Biosystems) and gene-specific expression assays for MASTL (Hs00949171.m1), FOXM1 (Hs01073586.m1) and GUSB (Hs99999908_m1). Relative mRNA levels were determined according to the delta-deltaCt method, and values were normalized to GUSB levels.
Clonogenic Assay
To measure clonogenic survival, cells were diluted to a single cell suspension and seeded in 25 cm 2 flasks as described in (11) . Flasks were irradiated with a single dose of γ-radiation in the range of 0-6 Gy. Cells were grown for a period of 7-21 days. Subsequently, cells were fixed with 100% EtOH and stained with Giemsa's azur eosin methylene blue solution (Merck). Colonies of more than 50 cells were counted.
Western blotting
Western blots were performed according to standard procedures (12) . Proteins were separated by SDS-PAGE and blotted on PVDF membranes (Millipore). Antibodies used for detection were mouse anti-ATM (sc-23921), mouse anti-pATM (sc-47739), rabbit anti-FOXM1 (sc-502; Santa Cruz), rabbit anti-ENSA (D5Z1U), rabbit anti-pENSA (S67), Rabbit anti-MASTL (D3J4Y; Cell Signaling Technology) and mouse anti-β-actin (AC-15; Sigma-Aldrich).
Proteins were visualized using the secondary fluorescently-labeled antibodies goat-anti-mouse
IRDye 680 RD and goat-anti-rabbit IRDye 800 CW; LI-COR Biosciences) and scanned on the Odyssey infrared imaging system (LI-COR Biosciences).
Fractionated irradiation
Cells were seeded at low density in 25 cm 2 flasks, after which they were irradiated on 5 sequential days with a dose of 2 Gy. After 2 days of recovery, the total number of cells was determined by cell counting and the cells were irradiated again using the same schedule. The schedule was repeated for 6 weeks in total, after which the cells had received a cumulative dose of 60 Gy.
Xenograft studies in mice
In total 1.4x10 6 A549 cells transduced with MASTL shRNA were injected in both flanks of immune deficient athymic NU/NU mice (Harlan). At day 6, 10 and 13 the mice received 2 Gy of total body irradiation on a linear accelerator. Tumor growth was measured twice a week by caliper measurement. After four weeks the mice were euthanized and all tumors frozen.
Experiments were performed in accordance to Dutch legislations, and the protocol was approved by the Institutional Review Board on animal experimentation.
Cell cycle analysis
Cultured SW1573 cells were labeled with 2.5 µM Bromodeoxyuridine (BrdU) for 20 minutes at 37˚C for FACS analysis. Cells were harvested by trypsinization and fixed in 70% EtOH.
The samples were left at 4˚C overnight, after which the cells were centrifuged and 
Confocal imaging
Results
Genome wide loss of function screen for radiosensitizers
In our functional genetic screen we tested siRNAs targeting over 21,000 human genes for their capacity to induce radiosensitization in the NSCLC cell line SW1573. This NSCLC cell line is relatively resistant to ionizing radiation in comparison to other cell lines tested (data not shown) and could therefore be sensitized to radiation. As a control, radiosensitization was achieved by siRNA mediated knockdown of protein kinase, DNA activated, catalytic polypeptide (PRKDC), which is known for its role in the DNA damage response (Supplementary Figure 1A , (13)).
To identify other unique siRNAs that could sensitize SW1573 cells to irradiation, cells were controls and thus sensitized SW1573 to radiation in this screen (p<1x10 -6 , t-test for independent samples), indicating that the screen was sensitive enough to identify relevant radiosensitizing siRNAs. To generate a list of putative hits in the screen we set a cut-off at a robust Z-score of -2.75, at which more than 95% of the siPRKDC and less than 0.5% of the siCON controls were scored as hits. Using this cut-off value a total of 433 siRNAs were identified that potentially sensitize SW1575 to radiation (Supplementary Table 1) .
Interestingly, several genes involved in the DNA damage response were amongst these hits, such as RAD51, TOPBP1, HTATIP, RNF168, PNKP and TRIM28 (15) (16) (17) (18) (19) . A more detailed pathway analysis of the hits using Ingenuity Pathway Analysis software (www.ingenuity.com) showed that proteins belonging to specific cellular functions, such as cell cycle control as well as cell death and survival, were significantly overrepresented in the hit list ( Table 1) . As the function of cell cycle proteins is frequently altered in cancer, we focused in more detail on this cluster of hits, especially since cell cycle checkpoints are often activated after irradiation to allow DNA damage repair ( Figure 1C ) (20) . The list of cell cycle related genes contains many novel targets that could possibly be inhibited by small molecules to obtain radiosensitivity, of which the kinase microtubule associated serine/threonine kinaselike (MASTL) was one of the top hits with a robust Z-score of -4.55. As MASTL is a protein kinase it is potentially druggable and was therefore chosen for further follow up. Next to MASTL we also chose another cell cycle related gene for further validation. This gene, with a higher robust Z-score of -2.86, Forkhead box M1 (FOXM1) was chosen for validation experiments to show the validity of our obtained hit list. Inhibition of FOXM1 was recently shown to cause radiosensitization in a variety of cancer cells and therefore could prove that even the lower ranked hits in our hit list are potent radiosensitizers (21). To validate the radiosensitizing effect of two of the hits, MASTL and FOXM1, the separate siRNAs from the original pool were tested for their effect on the radiation response. All 4 individual siRNAs directed towards both FOXM1 and MASTL were enhancing the effect of 2 Gy of radiation on SW1573 cells (Figure 2A and B) . To investigate possible effects of inhibition of FOXM1 and MASTL on the growth rate of untreated cells, the relative survival without radiation treatment was analyzed. This experiment showed that knockdown of these genes did not negatively affect the growth rate of untreated cells ( Figure 2C and D) . To show that the siRNAs specifically decrease the RNA levels of their targeted genes we performed a qPCR analysis on the siRNA transfected cells. This analysis confirmed that all siRNAs decreased the mRNA levels of their target genes generally more than 80% in comparison to the controls (Supplementary Figure 2A and B).
Inhibition of FOXM1 or MASTL induces radiosensitivity
As our high-throughput assay to analyze radiosensitization is based on counting the nuclei of the total population of cells, we also validated our findings using the gold standard for analyzing radiosensitivity, the clonogenic assay. Also this assay showed that knockdown of either FOXM1 or MASTL sensitizes SW1573 cells to radiation ( Figure 2E and F).
To independently validate our screening results, we decided to use short hairpin RNA (shRNA) expressing vectors instead of siRNAs for stable knockdown of the target genes. For both target genes, we selected 2 shRNA vectors that gave a knockdown of over 70% at the RNA and protein level in SW1573 cells ( Figure 3A-D) and determined the sensitivity to radiation of SW1573 stably expressing these constructs. Indeed, also these shRNA expressing cell lines were more sensitive to radiation compared to the controls in a clonogenic assay consecutive days and left untreated for two days, after which this cycle was repeated 5 times.
The number of control cells rapidly increased in the first two weeks of treatment, after which a plateau was reached. Interestingly, the total number of shMASTL cells increased only in the first week of treatment after which a plateau was reached at a significantly lower number of cells in comparison to the control ( Figure 3G ). Next, we checked the cell cycle status of MASTL knockdown cells two weeks in the fractionated dose scheme. This analysis showed an almost complete absence of S-phase, without an increase in the sub-G1 population after two weeks of irradiation (Supplementary Figure 2C) . These results suggest that decreased levels of MASTL lead to an altered cell cycle dynamics after radiation, without an induction of apoptosis.
To exclude a possible cell line specific effect, we determined the effect of 
Effect of MASTL on radiosensitivity in vivo
As indicated above, MASTL knockdown cells only showed an altered growth rate when they were treated with radiation. Therefore we also tested the sensitivity of these cells to radiation in vivo. As SW1573 did not give rise to xenografts, we used A549 cells transduced with 
MASTL shRNA for these experiments. These experiments were hampered by the observation that only a 60% knockdown of MASTL expression was obtained in A549 cells (Supplementary Figure 3) . Nonetheless, these cells were injected in the flanks of 16 nude mice, of which 8 mice were left untreated and the other 8 mice were treated with 2 Gy of total body irradiation at days 6, 10 and 13 after injection of the cells. After 4 weeks of growth no significant difference in tumor volume was observed between irradiated shMASTL transduced xenografts or irradiated control transduced xenografts (data not shown). Based on the modest knockdown we assumed that the cultures consisted of cell populations with variable levels of MASTL knockdown, and hypothesized that the populations with the most efficient knockdown would be preferentially eradicated by irradiation. We therefore isolated the RNA from the resulting tumors and analyzed MASTL expression by RT-qPCR. As can be seen in Figure 4E , MASTL expression increased significantly after irradiation (p<0.001) in comparison to the untreated tumors, which suggest that cells with a relatively efficient MASTL knockdown were preferentially eradicated by irradiation in vivo.
Altered phosphorylation upon MASTL knockdown
As MASTL is a kinase we wondered which substrates would be causative for the observed effects. Endosulfine alpha (ENSA) has been shown to be a substrate for MASTL kinase in Xenopus laevis, where it appears to play a role in the mitosis by regulating cyclinB-CDK1 activity (22) . As the G2/M checkpoint is critically important in the response to DNA damage we wondered whether the regulation of ENSA activity by MASTL is involved in the observed phenotype after irradiation. Western blot analysis of shMASTL transduced SW1573 cells did not show an altered level of pENSA compared to control cells despite a substantial reduction of MASTL protein ( Figure 5A and B) . As the shMASTL expressing cells only showed a phenotypic effect after irradiation, we also analyzed the pENSA levels after irradiation. Surprisingly, the levels of pENSA were not altered in the first two hours after irradiation either ( Figure 5C ). Together these data suggest that ENSA is not the key substrate of MASTL that is causative for the altered response to radiation in the cells used in our studies.
In order to identify other candidate proteins that have an altered phosphorylation level after MASTL knockdown, we performed a phosphoproteomics analysis on the MASTL knockdown cells in the absence and presence of irradiation. In total 8,410 peptides were identified in the phosphopeptide enriched samples, of which 7,603 were validated to be phosphopeptides. In total 8,263 phosphorylation sites were detected in the samples, of which 7,136 pSerine (86.4%), 1,082 pThreonine (13.1%) and 45 pTyrosine (0.5%).
In comparison to the control, 392 peptides corresponding to 254 unique proteins were at least 2-fold less phosphorylated after MASTL knockdown, including MASTL itself (Supplementary Table 2 ). After irradiation a total number of 363 peptides from 220 unique proteins were at least 2-fold less phosphorylated (Supplementary Table 3 In contrast to what had been observed in the phosphoproteomics data for DNA damage response proteins, we also identified a large number of proteins that had significantly lower phosphorylation levels in MASTL knockdown cells. DAVID software analysis of these proteins showed that a number of functional clusters were highly enriched in this list (Supplementary Table 5 ). A cluster involved in cell cycle regulation was highly enriched in the list with lower phosphorylation levels after MASTL knockdown (Enrichment score: 5.1, Figure 5F and Supplementary Table 5 and 6), which suggests that after MASTL knockdown a number of proteins involved in cell cycle regulation seem to be significantly altered in their phosphorylation state. Of note, our data cannot exclude that these proteins are indirect targets of MASTL knockdown.
Inhibition of MASTL induces alterations in cell cycle progression after irradiation
As the phosphoproteomics analyses suggested that MASTL inhibition directly or indirectly affects the phosphorylation of a large number of proteins involved in cell cycle regulation, we determined the effect of MASTL knockdown on the growth of SW1573. SW1573 cells with lowered levels of MASTL seem to proliferate at the same rate as control cells (Supplementary Figure 4A) . However, when these cells are challenged with DNA damage caused by 2 Gy of irradiation, the total number of cells is decreased in comparison to the controls ( Figure 6A ). analysis. This suggests that BUB1 might be a critical target for MASTL-mediated phosphorylation leading to its activation. We therefore also tested the effect of decreased BUB1 protein levels on the response to radiation, Figure 6F shows that also BUB1 knockdown leads to radiosensitization of SW1573 cells ( Figure 6F , Supplementary Figure   5C ). All in all these results suggest that absence of MASTL and thereby an improper activation of BUB1 might lead to an improper SAC and a premature restart of cell division after radiation. 
Discussion
In lung cancer treatment, radiotherapy is often combined with concomitant application of platinum-based chemotherapeutics (24). Platinum-associated toxicities, however, can be severe and often the treatment protocol has to be adapted to deal with this. We hypothesized that there might be many druggable genes that influence radiation-induced damage, which could be exploited to enhance the efficacy of radiotherapy, preferentially with much less toxicities.
Here we report an unbiased genome-wide loss-of-function screen to identify novel targets for radiosensitization in NSCLC. Using a library of siRNAs targeting approximately 21,000 unique human genes we identified that the knockdown of 433 genes putatively sensitize NSCLC cells to ionizing radiation. Indeed, we could confirm that 2 genes from our hit list, FOXM1 and MASTL, are also modulators of the response to irradiation. Importantly, knockdown of these genes had large effects on radiosensitivity in cancer cells, but only minor effects were observed in normal primary fibroblasts, which might increase the therapeutic window.
FOXM1 has only recently been implicated in the response to DNA damage in pancreatic and breast cancer cell lines (21) . On top of that, FOXM1 has been shown to mediate resistance to different drugs, such as herceptin, paclitaxel, cisplatin and epirubicin (25) (26) (27) (28) . We showed that FOXM1 knockdown also leads to radiosensitization in NSCLC cell lines. All these studies indicate that FOXM1 regulates cellular processes that are of importance for the response to a variety of therapeutics currently used in the clinic. It would therefore be of great interest to investigate the effect of FOXM1 inhibitors on the response to combinations of the specific treatments.
Next to FOXM1, we could also validate that knockdown of MASTL leads to clear that this protein plays an important role in the G2/M-phase of the cell cycle (29, 30) , and our data confirm that. Depletion of Greatwall kinase, the Xenopus homolog of MASTL, prevented mitotic entry in Xenopus egg extracts (29, 30) . This finding was later confirmed in human cells, where nearly complete knockdown of MASTL led to a severe delay in mitotic entry (31, 32) . Strikingly, cells with a partial knockdown of MASTL could enter mitosis normally, but exited prematurely, leading to cytokinesis defects (31, 32) . In our study, where a partial knockdown of MASTL was achieved, a faster exit of cells from the radiation-induced G2/M arrest was observed, suggesting that these cells are exiting mitosis prematurely after encountering DNA damage. This is further strengthened by our observation of more chromatin bridges in MASTL knockdown cells after irradiation. The observed cell cycle arrest in cells exposed to a fractionated dose scheme of irradiation is therefore likely to be caused by a response to the cytokinesis defects that were also observed in earlier studies (31, 32) .
The radiosensitizing effect of MASTL knockdown did not seem to be driven by ENSA, the currently known substrate for MASTL (22, 33) , as we could not confirm an altered phosphorylation state of this protein after MASTL knockdown. Our phosphoproteomics analysis further suggests that the initial phosphorylation of DNA damage response proteins is not altered in irradiated cells with lowered MASTL expression. Hence, these proteins do not seem to be MASTL substrates as well. In contrast, the phosphorylation of a number of cell cycle related proteins was significantly reduced after MASTL knockdown. Strikingly, it has previously been suggested that Greatwall kinase has a role in DNA-damage checkpoint activation and recovery in a cell free system (34) . Our study suggests that MASTL knockdown has an effect on cell cycle progression of irradiated cells, likely through the regulation of cell Strikingly, the radiosensitizing effect of MASTL knockdown had a major effect on cells treated by a fractionated schedule in vitro, which implies that it might be a potent targeted radiosensitizer. Remarkably, there are no small molecule inhibitors described for MASTL, even though it is a kinase. Our work might be therefore be a starting point to develop a novel class of targeted inhibitors that may act as radiosensitizers to enhance the effect of radiation on tumor cells with MASTL as prime candidate. 
